BOCIC(SH:601696) Xin Lang Cai Jing·2025-10-21 06:13Core Viewpoint - Baipusais Biotechnology Co., Ltd. has shown a significant stock price increase of 5.03%, reaching 61.21 CNY per share, with a total market capitalization of 10.274 billion CNY as of October 21 [1] Company Overview - Baipusais Biotechnology Co., Ltd. was established on July 22, 2010, and went public on October 18, 2021. The company is located in Beijing Economic and Technological Development Zone [1] - The main business involves providing key biological reagent products and technical services, with revenue composition as follows: 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [1] Fund Holdings - According to data, a fund under Bank of China Securities holds a significant position in Baipusais, with 99,000 shares, accounting for 4.48% of the fund's net value, making it the seventh-largest holding [2] - The fund, named Bank of China Securities Health Industry Mixed Fund (002938), has a total scale of 158 million CNY and has achieved a year-to-date return of 42.47%, ranking 1188 out of 8162 in its category [2] Fund Manager Information - The fund manager of Bank of China Securities Health Industry Mixed Fund is Li Mingwei, who has been in the position for 2 years and 243 days. The fund's total asset size is 158 million CNY [3] - During Li Mingwei's tenure, the best fund return was -4.25%, and the worst was also -4.25% [3]